Toray Of Japan Accelerates Anti-Itching Agent Clinical Trails In Europe And U.S.
This article was originally published in PharmAsia News
Currently under approval review in Japan, Toray has sped up the clinic trials overseas for anti-itching agent TRK-820, jointly developed by Toray, Japan Tobacco, Torii Pharma and Maruo Co. In Europe, TRK-820 injection has entered a Phase III trial, and a Phase III trial for TRK-820 oral dose has begun in the U.S. TRK-820 is an opioid k receptor agonist for treating uremic pruritis in hemodialysis patients. Toray hopes to get TRK-820 oral dose approved in Japan within this year. The company also announced that urinary incontinence drug TRK-130 has entered Phase II trials in Japan. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.